# NORDIC BIOSCIENCE HOLDING A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/nordicbioscienceholding). ## Overview NORDIC BIOSCIENCE HOLDING A/S is a Danish holding company with consolidated accounts, headquartered in Hellerup, Denmark. The available filing excerpt does not disclose the operating business of the group, so the company can only be identified here as a corporate holding structure rather than a specific operating product company. ## Products & services • Consolidated holding and group management • Ownership of subsidiary investments • Capital allocation across group entities • Corporate administration and reporting - **Holding company services** (100%) — Corporate ownership, governance, and oversight of consolidated subsidiaries. - Consolidated holding and group management - Ownership of subsidiary investments - Capital allocation across group entities - Corporate administration and reporting ## Customers The available information does not identify external customer segments or end markets for the group. As a holding company, its value is likely derived from ownership and oversight of subsidiaries rather than direct sales to customers. - **Subsidiary investments** (primary) — The holding company’s economic exposure is to its controlled group companies and their underlying businesses. - No external customer base is disclosed in the available filing excerpt - Value likely comes from subsidiary ownership and governance - Potential customers cannot be verified from the provided context - No end-market or channel disclosure is available ## Geography The company is based in Denmark, with its registered address in Hellerup. No revenue geography, operating country, or international market breakdown is disclosed in the provided material, so the business footprint cannot be reliably mapped beyond the Danish parent entity. - Headquartered in Hellerup, Denmark - No revenue-by-country disclosure is available - No operating country list is disclosed in the excerpt - Geographic exposure cannot be inferred from the filing text ## Strategy The available excerpt does not disclose a business strategy, operational priorities, or market expansion plan. For a holding company, the strategic focus would typically center on portfolio ownership, capital allocation, and subsidiary oversight, but those specifics are not stated here. - No explicit strategy is disclosed in the available filing excerpt - Likely focus is on portfolio ownership and group oversight - Capital allocation would depend on subsidiary performance - No market, product, or operating strategy can be verified ## Risks The main identifiable risk is information risk: the provided material does not disclose the operating business, revenue base, or customer exposure of the group. As a holding structure, the company would also be exposed to subsidiary performance, valuation uncertainty, and dependence on the value of its investments, but the excerpt does not provide enough detail to quantify those risks. - **Undisclosed operating business** [medium] — The filing excerpt does not identify what the group actually sells or where it operates, limiting investor visibility. - **Subsidiary valuation and impairment** [high] — A holding company depends on the carrying value of investments, which can be sensitive to underlying performance and fair value assumptions. - Operating business is not disclosed in the provided excerpt - Subsidiary value and impairment risk are likely relevant - Portfolio concentration risk cannot be assessed from the text - No customer, market, or geography risk detail is available ## Accounting The key accounting issue for this profile is consolidation and the valuation of investments in subsidiaries, associates, or other financial assets. Because the excerpt contains only corporate filing identifiers and equity movement references, the material judgment areas appear to be group consolidation, investment carrying values, and any exchange-difference reserves rather than operating revenue recognition. - **Consolidation accounting** — Affects balance sheet and group-level equity - **Investment impairment** — Can materially affect profit and equity - **Foreign currency translation** — Impacts other comprehensive income and equity - Consolidation scope affects which entities are included in results - Investment carrying values may depend on fair value or impairment testing - Exchange translation reserves may affect equity presentation - No revenue-recognition detail is available in the excerpt --- *Last updated: 2026-10-24T15:14:08.550651+00:00*